# A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

> **NCT06594965** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 176 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Anemia
- MDS
- Bone Marrow Disease

## Interventions

- **DRUG:** HS-20106

## Key facts

- **NCT ID:** NCT06594965
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594965, "A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06594965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*